keyword
MENU ▼
Read by QxMD icon Read
search

Drug pricing

keyword
https://www.readbyqxmd.com/read/30221755/nusinersen-treatment-of-spinal-muscular-atrophy-current-knowledge-and-existing-gaps
#1
REVIEW
Teresa Gidaro, Laurent Servais
Spinal muscular atrophy (SMA) is a recessive disorder caused by a mutation in the survival motor neuron 1 gene (SMN1); it affects 1 in 11 000 newborn infants. The most severe and most common form, type 1 SMA, is associated with early mortality in most cases and severe disability in survivors. Nusinersen, an antisense oligonucleotide, promotes production of full-length protein from the pseudogene SMN2. Nusinersen treatment prolongs survival of patients with type 1 SMA and allows motor milestone acquisition...
September 17, 2018: Developmental Medicine and Child Neurology
https://www.readbyqxmd.com/read/30218844/rationale-and-design-of-the-evolve-short-dapt-study-to-assess-3-month-dual-antiplatelet-therapy-in-subjects-at-high-risk-for-bleeding-undergoing-percutaneous-coronary-intervention
#2
Laura Mauri, Ajay J Kirtane, Stephan Windecker, Robert W Yeh, Harold L Dauerman, Matthew J Price, Thomas Christen, Dominic J Allocco, Ian T Meredith, Dean J Kereiakes
BACKGROUND: While extended dual antiplatelet therapy (DAPT) with aspirin and a platelet (P2Y12 ) inhibitor after percutaneous coronary intervention (PCI) reduces the risk of stent thrombosis (ST) and myocardial infarction (MI), it also increases bleeding. Newer generation drug-eluting stents with bioabsorbable polymer coatings may reduce thrombotic events and allow abbreviated DAPT in selected patients. The EVOLVE Short DAPT study is designed to evaluate the safety of 3-month DAPT in high bleeding risk subjects treated with the SYNERGY bioabsorbable polymer everolimus-eluting stent...
August 17, 2018: American Heart Journal
https://www.readbyqxmd.com/read/30218454/the-american-cancer-patients-first-plan-to-reduce-drug-prices-a-critical-assessment
#3
Hagop Kantarjian, Donald W Light, Vivian Ho
No abstract text is available yet for this article.
September 14, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30217656/new-synthetic-opioids-part-of-a-new-addiction-landscape
#4
REVIEW
Laurent Karila, Maude Marillier, Boris Chaumette, Joel Billieux, Franchitto Nicolas, Benyamina Amine
Synthetic opioids (SO) are a major risk for public health across the world. These drugs can be divided into 2 categories, pharmaceutical and non-pharmaceutical fentanyls. A new generation of SO has emerged on the drug market since 2010. North America is currently facing an opioid epidemic of morbi-mortality, caused by over-prescription of opioids, illegally diverted prescribed medicines, the increasing use of heroin, is and the emergence of SO. Furthermore, this opioid crisis is also seen in Europe. SO are new psychoactive substances characterized by different feature such as easy availability on the Internet, low price, purity, legality, and lack of detection in laboratory tests...
September 11, 2018: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/30215707/the-availability-price-and-affordability-of-antidiabetic-drugs-in-hubei-province-china
#5
Shiwei Gong, Hongbing Cai, Yufeng Ding, Weijie Li, Xu Juan, Jinlan Peng, Si Jin
Based on the high prevalence and undiagnosed rate of diabetes mellitus in China in recent years, the aim of this work was to evaluate the availability, price and affordability of pharmacotherapy for diabetes in public hospitals in Hubei province, China. In 2016, a cross-sectional survey was conducted using World Health Organization/Health Action International (WHO/HAI) methodology. Information on the availability and prices of 20 antidiabetic drugs was collected from 34 public hospitals representing three levels of care...
September 11, 2018: Health Policy and Planning
https://www.readbyqxmd.com/read/30215535/fair-global-drug-pricing
#6
Jonathan D Campbell, Zoltán Kaló
No abstract text is available yet for this article.
September 14, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/30211342/therapeutic-opportunities-for-pain-medicines-via-targeting-of-specific-translation-signaling-mechanisms
#7
Salim Megat, Theodore J Price
As the population of the world ages and as more and more people survive diseases that used to be primary causes of mortality, the incidence of severe chronic pain in most of the world has risen dramatically. This type of pain is very difficult to treat and the opioid overdose epidemic that has become a leading cause of death in the United States and other parts of the world highlights the urgent need to develop new pain therapeutics. A common underlying cause of severe chronic pain is a phenotypic change in pain-sensing neurons in the peripheral nervous system called nociceptors...
August 2018: Neurobiology of Pain
https://www.readbyqxmd.com/read/30211247/outpatient-parenteral-antimicrobial-therapy-among-people-who-inject-drugs-a-review-of-the-literature
#8
REVIEW
Joji Suzuki, Jennifer Johnson, Mary Montgomery, Margaret Hayden, Christin Price
Hospitalizations for people who inject drugs (PWID) with infectious complications requiring prolonged antibiotic therapy are increasing in the context of the opioid epidemic. Although outpatient parenteral antimicrobial therapy (OPAT) is routinely offered to patients without a history of injection drug use (IDU), PWID are often excluded from consideration of OPAT. To better assess the evidence base for the safety and effectiveness of OPAT for PWID, we conducted a review of the published literature. Results suggest that OPAT may be safe and effective for PWID, with rates of OPAT completion, mortality, and catheter-related complications comparable to rates among patients without a history of IDU...
September 2018: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/30210343/screening-pregnant-women-and-their-neonates-for-illicit-drug-use-consideration-of-the-integrated-technical-medical-ethical-legal-and-social-issues
#9
REVIEW
Hayley R Price, Abby C Collier, Tricia E Wright
North America is currently suffering from one of the worst epidemics of illicit drug use in recent history: the opioid crisis. Pregnant women are not immune to the ravages of substance misuse which affects themselves, their pregnancies, and the wider community. The prevalence of drug misuse in pregnancy is not well quantified due to the lack of good validated tests, cooperation between clinicians and scientists developing tests, and consensus as to who should be tested and how results should be used. A wide range of tissues can be tested for drug use, including maternal blood, urine, and hair; neonatal meconium, urine, and hair; and placenta and umbilical cord tissues...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/30209955/the-use-of-antiplatelet-agents-after-an-acute-coronary-syndrome-in-a-large-community-italian-setting-of-more-than-12-million-subjects
#10
Aldo P Maggioni, Letizia Dondi, Antonella Pedrini, Giulia Ronconi, Silvia Calabria, Claudio Cimminiello, Nello Martini
BACKGROUND: Antiplatelet agents are the cornerstone of medical treatment in acute coronary syndromes. The aim of this study was to evaluate the clinical epidemiology of patients after an acute coronary syndrome treated with different antiplatelet agent regimens in a large real community setting. METHODS: The ARCO database, including more than 12 million inhabitants, was evaluated. Antiplatelet agent prescriptions were analysed as follows: aspirin, clopidogrel, other antiplatelet agents used alone; the free and fixed combination of clopidogrel and aspirin; the free combination of aspirin with other antiplatelet agents...
September 13, 2018: European Heart Journal. Acute Cardiovascular Care
https://www.readbyqxmd.com/read/30199170/state-remedies-for-costly-prescription-drugs
#11
Richard Cauchi
(1) At least 74.7 million Americans use three or more prescription drugs in a 30-day period. (2) Eighty percent of the U.S. public views prescription drug costs as "unreasonable," while 17 percent say “reasonable,” according to a recent poll. (3) An influenza drug has a cash price of $100, but a patient with insurance may pay $125 because of a “gag clause” that restricts pharmacists from disclosing price options.
August 2018: NCSL Legisbrief
https://www.readbyqxmd.com/read/30199167/pharmaceutical-reference-pricing-does-it-have-a-future-in-the-u-s
#12
Jame C Robinson
Issue: Reference pricing is an emerging health insurance benefit design aimed at reducing health costs. In this model, an insurer establishes a maximum payment that it will contribute toward covering the price of a product or service in situations where there is wide price variation for therapeutically similar drugs, diagnostics, or procedures. Experiences to date indicate that reference pricing can influence patients and physicians to switch to less costly options within each therapeutic class, reducing overall drug prices...
September 1, 2018: Issue Brief of the Commonwealth Fund
https://www.readbyqxmd.com/read/30198061/multi-indication-pricing-nice-in-theory-but-can-it-work-in-practice
#13
Jorge Mestre-Ferrandiz, Néboa Zozaya, Bleric Alcalá, Álvaro Hidalgo-Vega
For medicines with different valued indications (uses), multi-indication pricing implies charging different prices for different uses. In this article, we assess how multi-indication pricing could help achieve overall strategic objectives of pricing controls, summarise its advantages and disadvantages (vs. uniform pricing) and estimate the hypothetical impact on prices of moving towards multi-indication pricing for specific oncologic medicines in Spain. International experience shows that multi-indication pricing can be implemented in real practice, and indeed a few initiatives are currently in use, albeit mostly applied indirectly through confidential pricing agreements that offer a way to discriminate prices across countries without altering list prices...
September 10, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/30196515/cost-evolution-of-biological-agents-for-the-treatment-of-spondyloarthritis-in-a-tertiary-hospital-influential-factors-in-price
#14
Mariángeles González-Fernández, Elena Villamañán, Inmaculada Jiménez-Nácher, Francisco Moreno, Chamaida Plasencia, Francisco Gaya, Alicia Herrero, Alejandro Balsa
Background Spending on biological agents has risen dramatically due to the high cost of the drugs and the increased prevalence of spondyloarthritis. Objective To evaluate the annual cost per patient and cost for each biological drug for treating patients with spondyloarthritis from 2009 to 2016, and to calculate factors that affect treatment cost, such as optimizing therapies by monitoring drug serum levels, the use of biosimilar-TNF inhibitors, and official discounts or negotiated rebates in biologicals acquired by the pharmacy department...
September 8, 2018: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/30195093/drug-policy-in-greece
#15
John N Yfantopoulos, Athanasios Chantzaras
OBJECTIVES: To provide a detailed overview of the recent reforms in pharmaceutical pricing and reimbursement processes as well as in other important areas of the pharmaceutical policy in Greece. METHODS: Information was collected via a structured questionnaire. The study used publicly available resources, such as publications, relevant legislation, and statistical data, while health experts were also consulted. RESULTS: Recent pharmaceutical reforms included significant price cuts, increased co-payments and some provisions for vulnerable groups, rebates/clawbacks, mandatory electronic prescribing and prescription by international nonproprietary name, generics substitution, prescription limits and detailed auditing, centralized procurement, as well as changes in the pricing and reimbursement processes, with the introduction of positive and negative lists and an internal price referencing system...
September 5, 2018: Value in Health Regional Issues
https://www.readbyqxmd.com/read/30195080/manufacturing-and-characterization-of-long-acting-levonorgestrel-intrauterine-systems
#16
Quanying Bao, Bing Gu, Claire F Price, Yuan Zou, Yan Wang, Darby Kozak, Stephanie Choi, Diane J Burgess
Mirena® is long-acting (5 years) contraceptive intrauterine device. It is composed of a hollow cylindrical drug reservoir (containing Levonorgestrel and polydimethylsiloxane), which is covered with a release rate controlling silicone membrane. This structure presents a manufacturing challenge and to date, there have been no literature reports on the manufacturing, product design and quality evaluation of these hollow cylindrical intrauterine devices. It is vital to develop a reproducible and robust manufacturing process for these long-acting intrauterine devices or systems to obtain an understanding the in vitro and in vivo performance of such drug-device combinations...
September 5, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/30194067/us-hospitals-launch-non-profit-generic-drug-producer-to-counter-rising-prices
#17
Bob Roehr
No abstract text is available yet for this article.
September 7, 2018: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/30193913/a-brief-survey-to-identify-pregnant-women-experiencing-increased-psychosocial-and-socioeconomic-risk
#18
Anna Price, Hannah Bryson, Fiona Mensah, Lynn Kemp, Charlene Smith, Francesca Orsini, Harriet Hiscock, Lisa Gold, Ashlee Smith, Lara Bishop, Sharon Goldfeld
PROBLEM: Identifying pregnant women whose children are at risk of poorer development in a rapid, acceptable and feasible way. BACKGROUND: A range of antenatal psychosocial and socioeconomic risk factors adversely impact children's health, behaviour and cognition. AIM: Investigate whether a brief, waiting room survey of risk factors identifies women experiencing increased antenatal psychosocial and socioeconomic risk when asked in a private, in-home interview...
September 4, 2018: Women and Birth: Journal of the Australian College of Midwives
https://www.readbyqxmd.com/read/30192777/associations-between-health-systems-capacity-and-mother-to-child-hiv-prevention-program-outcomes-in-zambia
#19
Joan T Price, Benjamin H Chi, Winifreda M Phiri, Helen Ayles, Namwinga Chintu, Roma Chilengi, Jeffrey S A Stringer, Wilbroad Mutale
INTRODUCTION: Zambia has made substantial investments in health systems capacity, yet it remains unclear whether improved service quality improves outcomes. We investigated the association between health system capacity and use of prevention of mother-to-child HIV transmission (PMTCT) services in Zambia. MATERIALS AND METHODS: We analyzed data from two studies conducted in rural and semi-urban Lusaka Province in 2014-2015. Health system capacity, our primary exposure, was measured with a validated balanced scorecard approach...
2018: PloS One
https://www.readbyqxmd.com/read/30186021/wide-ranging-trump-drug-price-reduction-blueprint-controversial-issues-included-some-excluded
#20
Stephan Barlas
President Trump's American Patients First plan to reduce drug prices has some innovative aspects but might face political roadblocks.
September 2018: P & T: a Peer-reviewed Journal for Formulary Management
keyword
keyword
109177
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"